autoimmune inner ear disease (aied) bastaninejad, shahin, md assistant professor of orl-hns, tums,...
TRANSCRIPT
Autoimmune Inner Ear Autoimmune Inner Ear Disease Disease ((AIEDAIED))
Bastaninejad, ShahinBastaninejad, Shahin, , MDMD
Assistant Professor of ORL-HNS, TUMS, AmirAlam Assistant Professor of ORL-HNS, TUMS, AmirAlam HospitalHospital
Case PresentationCase Presentation
45yrs female45yrs female
Right sided hearing Right sided hearing loss and aural loss and aural fullness, fullness, dysequilibrium dysequilibrium progressive over 2 progressive over 2 months months
Normal Px, except Normal Px, except Weber testWeber test
CBC, chemistries, CBC, chemistries, TFTs, RPR, ESR were TFTs, RPR, ESR were normalnormal
MRI MRI Normal Normal
Low salt diet,
Thiazide diuretics
At follow-up, Left At follow-up, Left
hearing worsedhearing worsed
Prednisone 60 mg
Daily
Serum anti-68kDa
protein positive
On steroids, Hearing On steroids, Hearing
improvedimproved
While steroid taper While steroid taper
down, one relapse down, one relapse
occuredoccured, again with , again with
improvement on improvement on
steroidssteroids
Presentation OutlinesPresentation Outlines
DefinitionDefinition
Epidemiology & PathogenesisEpidemiology & Pathogenesis
Clinical PresentationClinical Presentation
Differential DiagnosisDifferential Diagnosis
Laboratory and paraclinical work upLaboratory and paraclinical work up
TreatmentTreatment
Secondary AIEDSecondary AIED
DefinitionDefinition
• AIEDAIED (McCabe 1979):– Rapidly progressive SNHL (over a course of
weeks to months)– Bilateral– Responds to the administration of
corticosteroids
• ImportanceImportance: – AIED is one of the few medically reversible
causes of sensorineural hearing loss
DefinitionDefinition• Classification:
– PrimaryPrimary AIED AIED– SecondarySecondary AIED:
• SLE
• Ulcerative Colitis
• Cogan’s Syndrome
• Multiple Sclerosis
• Wegener’s Granulomatosis
• Various systemic vasculitides
• Sjogren’s Syndrome
• Celiac Disease
Presentation OutlinesPresentation Outlines
DefinitionDefinition
Epidemiology & PathogenesisEpidemiology & Pathogenesis
Clinical PresentationClinical Presentation
Differential DiagnosisDifferential Diagnosis
Laboratory and paraclinical work upLaboratory and paraclinical work up
TreatmentTreatment
Secondary AIEDSecondary AIED
Epidemiology & PathogenesisEpidemiology & Pathogenesis
• Primary AIED is a rare disorder
• True incidence is not clear. More common in middle aged woman
• Pathogenesis:– Although this disorder is likely immune mediated,
there is no there is no direct evidencedirect evidence that Primary AIED is that Primary AIED is autoimmune in etiology …autoimmune in etiology …
– inflammationinflammation lead to the fibrosis and osteoneogenesis of the cochlea
– Vasculopathy necrosis associated with vasculitis in the absence of inflammation
Presentation OutlinesPresentation Outlines
DefinitionDefinition
Epidemiology & PathogenesisEpidemiology & Pathogenesis
Clinical PresentationClinical Presentation
Differential DiagnosisDifferential Diagnosis
Laboratory and paraclinical work upLaboratory and paraclinical work up
TreatmentTreatment
Secondary AIEDSecondary AIED
Clinical Presentation
• The hearing loss may initially be unilateralmay initially be unilateral, and it may take months for the bilaterality to emerge
• Fluctuations in hearing may occurFluctuations in hearing may occur, but the overall course is one of a relentless deterioration in auditory function
• 50% 50% have Vestibular symptoms, in 20%20% of the cases Vertigo is like Meniere’s disease
Presentation OutlinesPresentation Outlines
DefinitionDefinition
Epidemiology & PathogenesisEpidemiology & Pathogenesis
Clinical PresentationClinical Presentation
Differential DiagnosisDifferential Diagnosis
Laboratory and paraclinical work upLaboratory and paraclinical work up
TreatmentTreatment
Secondary AIEDSecondary AIED
Differential Diagnosis
• Sudden deafnessSudden deafness– It’s mainly unilateral while AIED is bilateral– It is an emergency while AIED is not– It develops in less than 72hr but AIED
occurs in weeks to months– In SSNHL treatment window is 2 to 4 weeks,
but in a patient with AIED who develop SNHL in 6 to 12mo, we can still achieve significant recovery with corticosteroids
Differential Diagnosis• Meniere’s DiseaseMeniere’s Disease
– Very difficult to differentiate these two entities during Very difficult to differentiate these two entities during first months of evaluationfirst months of evaluation
– The only difference isThe only difference is: more aggressive course of : more aggressive course of AIED (regarding haring loss)AIED (regarding haring loss)
• OtosyphilisOtosyphilis• Acoustic neuromaAcoustic neuroma• MeningitisMeningitis• MSMS• MalignancyMalignancy (e.g., metastatic disease, lymphoma)
Presentation OutlinesPresentation Outlines
DefinitionDefinition
Epidemiology & PathogenesisEpidemiology & Pathogenesis
Clinical PresentationClinical Presentation
Differential DiagnosisDifferential Diagnosis
Laboratory and paraclinical work upLaboratory and paraclinical work up
TreatmentTreatment
Secondary AIEDSecondary AIED
Laboratory and Paraclinical work upLaboratory and Paraclinical work up• Lab:
– CBC/diff– ESR– RF– ANA, Anti-dsDNA, Anti-phospholipid– Anti-SSA/B– C3, C4 complement level– FTA-ABS– HIV– Western blotting for antibody against 68-kD Ag, or Anti-
HSP70 positive result may support the diagnosis of AIED, but can neither confirm nor rule out the diagnosisbut can neither confirm nor rule out the diagnosis
Laboratory and Paraclinical work upLaboratory and Paraclinical work up
• Paraclinics:Paraclinics:– MRI, Brain and Skull base, +/-Gd– ENG– MonthlyMonthly Audiometeric assesment
• About Anti-HSP70:About Anti-HSP70:– It is positive in 89% of AIED– Further studies have failed to show that this test
has sufficient sensitivity and specificity to rule in or rule out the diagnosis of AIED
• The diagnosis of primary AIED is based on
clinical evaluation, the demonstration of
progressive sensorineuralprogressive sensorineural hearing loss on
audiometric assessment done at monthly
intervals, and most importantly aa positive positive
response to the administration of response to the administration of
corticosteroidscorticosteroids
In summary
In summary
Presentation OutlinesPresentation Outlines
DefinitionDefinition
Epidemiology & PathogenesisEpidemiology & Pathogenesis
Clinical PresentationClinical Presentation
Differential DiagnosisDifferential Diagnosis
Laboratory and paraclinical work upLaboratory and paraclinical work up
TreatmentTreatment
Secondary AIEDSecondary AIED
TreatmentTreatment
• Corticosteroid therapy– In Adult patients start with 60mg/day for
4weeks (children 1mg/kg/day)– Taper down in 10-12 days in nonrespondersnonresponders– In respondersresponders (15dB Improvement in one freq.
or 10dB at two freq. or significant SDS improvement)…
TreatmentTreatment• …Continue full-dose therapy until monthly
audiograms reached a plateau of recovery
• Then taper it down slowly over 8 weeks to a maintenance dose maintenance dose of 10 to 20mg every other day
• Continue maintenance dose for a variable time (total treatment duration more than 6mo)(total treatment duration more than 6mo)
TreatmentTreatment• Other therapies:Other therapies:
– MTX (?) Steroid sparing (?)– CTX (Cyclophosphamide) severe side effects– Etanercept (?) inhibitor of TNF-alpha– IT Steroid therapy– IT TNF-alpha– Systemic IgG injection– Plasmapheresis– Cochlear implantationCochlear implantation
TreatmentTreatment
• The onlyThe only drug of proven utility in the drug of proven utility in the
management of AIED is management of AIED is CorticosteroidCorticosteroid
Presentation OutlinesPresentation Outlines
DefinitionDefinition
Epidemiology & PathogenesisEpidemiology & Pathogenesis
Clinical PresentationClinical Presentation
Differential DiagnosisDifferential Diagnosis
Laboratory and paraclinical work upLaboratory and paraclinical work up
TreatmentTreatment
Secondary AIEDSecondary AIED
Cogan’s SyndromeCogan’s Syndrome
• Interstitial keratitis
• vertigo, tinnitus,
SNHL
• archetypal
autoimmune inner
ear disease
Labyrinthine pathology may be coincident with the ocular Labyrinthine pathology may be coincident with the ocular manifestations or may occur up to 6 months before or after the manifestations or may occur up to 6 months before or after the onset of eye diseaseonset of eye disease
Vogt-Koyanagi-Harada (VKH) Vogt-Koyanagi-Harada (VKH) SyndromeSyndrome
• SNHL, Vestibular signs, Uveitis, …
• Periorbital hair loss and skin depigmentationPeriorbital hair loss and skin depigmentation
• Aseptic meningitis
• It may be autoimmunity to melanocytes
Wegener’s GranulomatosisWegener’s Granulomatosis• Necrotizing granulomata
• Vasculitis
• Respiratory tract and kidneys
involvement
• Serous OM
• C-ANCA 90% specific
• 30-50% ear involvement, 30-50% ear involvement,
usually middle ear, usually middle ear,
concomitant inner ear concomitant inner ear
involvement involvement 30% 30% SNHL SNHL
Polyarteritis NodosaPolyarteritis Nodosa
• Vasculitis of small and medium-sized
arteries
• Renal and visceral involvement
• Rarely rapidly progressive hearing loss
Behçet’s DiseaseBehçet’s Disease
Relapsing PolychondritisRelapsing Polychondritis
• Recurrent
inflammation of ear,
nose, trachea, larynx
• Autoantibodies to
cartilage
• NSAIDs, steroids,
dapsone
Systemic Lupus Systemic Lupus ErythematosusErythematosus
• Anti-nuclear, anti-DNA
antibodies
• Numerous systemic
manifestations
• COM with vasculitis,
SNHL (58%58%),
dysequilibrium
Rheumatoid ArthritisRheumatoid Arthritis
• Small joints of hands and feet
• Vasculitis, muscle atrophy, subcutaneous
nodules, splenomegaly
• 44% bilateral SNHL